SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
MTVA reported third quarter ended September 30, 2026 results. The price and volatility reaction is pending.
MTVAearnings

Earnings reactions, page 2

MetaVia Inc. (MTVA) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Research and Development (R&D) Expenses were approximately $2.6 million for the third quarter ended September 30, 2026, compared to approximately $1.9 million for the third quarter ended September 30, 2025.
  • General and Administrative (G&A) Expenses were approximately $2.1 million for the third quarter ended September 30, 2026, compared to approximately $1.6 million for the third quarter ended September 30, 2025.
  • Total Operating Expenses were approximately $4.7 million for the third quarter ended September 30, 2026, compared to approximately $3.5 million for the third quarter ended September 30, 2025.
  • Net Loss was $4.6 million, or $0.69 per basic and diluted share, for the third quarter ended September 30, 2026, compared with a net loss of $3.4 million, or $1.52 per basic and diluted share, for the third quarter ended September 30, 2025.
  • Cash and cash equivalents were $8.8 million as of September 30, 2026, compared with $10.3 million as of December 31, 2025.

Guidance

  • Full data from DA-1726 Phase 1 Parts 3A and 3B expected in the first quarter of 2027.
  • Initiation of a 48-week, non-biopsy Phase 2 study of DA-1726 in up to 150 subjects with MetALD and ALD is targeted for the second half of 2027.
  • Initiation of a randomized, 12-week Phase 2a non-biopsy proof-of-concept study of vanoglipel in combination with resmetirom is targeted for the first half of 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →